Navigate peer-reviewed breakthroughs by pharmacological class, genetic target, circulating biomarker, or diagnostic modality. Select any clinical entity to inspect all linked studies.
Everyday Health & Science Hubs
Indexed Entities (24)
Modality / Tech40 Peer-Reviewed Briefings
MRI, CT & Advanced Neuro/Thoracic Imaging
High-resolution magnetic resonance, low-dose computed tomography, PET tracers, and chest radiography.
Active Specialties:NeurologyOncologyNephrologyPulmonologyCardiologyImmunologyInfectious DiseasePharmacologyPsychiatryAI in MedicineGastroenterology
This case highlights fulminant cerebellitis as a life-threatening presentation of anti-GABA A R encephalitis and underscores the... She later stabilized with radiographic improvement and meaningful neurologic recovery.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
HI detected on pretreatment MRI is an independent predictor of poor long-term functional outcomes and correlates with post-MT PH/SICH.... Pre-MT HI may reflect significant blood-brain barrier disruption and microvascular fragility, serving as a marker of reperfusion vulnerability.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
In this interim analysis, short-course radiotherapy followed by camrelizumab and CAPOX significantly improved 3-year event-free survival in patients with locally advanced rectal cancer, with a safety profile similar to long-course chemoradiotherapy followed by CAPOX. Comparison of this promising new treatment strategy with contemporary total neoadjuvant therapy strategies is warranted.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
In an unselected, low-prevalence adult ICH population, ASL demonstrated excellent diagnostic accuracy and a near-perfect NPV, indicating that a negative ASL reliably excludes AVS. Main limitations include selective DSA use, few non-AVM shunts, and modest scanner heterogeneity.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
Readers will navigate a stepwise clinical reasoning approach to subacute cerebellar ataxia, which illustrates the importance of recognizing systemic red flags and monitoring phenotypic evolution as well as how specialized testing based on positive TBA results can resolve diagnostic dilemmas when commercial assays remain unrevealing. Specialized testing in a neuroimmunology laboratory ultimately revealed the diagnosis.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Current evidence consistently demonstrates that rs-fMRI acquired during the acute phase of brain injury is associated with neurologic and functional outcomes in patients with DoC. In addition, rs-fMRI may help identify patients more likely to recover consciousness and achieve favorable functional outcomes by characterizing the integrity of large-scale brain networks.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Follow-up MRI performed 1 month after presentation showed resolution of contrast enhancement and partial disappearance of spinal T2 hyperintense lesions. Negative infectious PCR testing and the absence of aquaporin 4 and myelin oligodendrocyte glycoprotein antibodies argued against infection or other inflammatory demyelinating condition.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Potosi virus can cause fatal neuroinvasive disease in humans, as evidenced by convergent postmortem neuropathologic, molecular, and ultrastructural evidence. Chronic B-cell depletion may increase susceptibility to severe disease with arboviral infections, which may present without conventional CNS inflammatory markers.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Small, cross-sectional, unmatched data require longitudinal validation of reproducibility, prognostic value, and clinical utility. Autosomal dominant polycystic kidney disease risk stratification relies on total kidney volume, a validated marker of cyst burden and progression.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
There was no other significant environmental history. The patient received anti-tubercular therapy along with tapering corticosteroids, showing initial clinical improvement.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Using coronary artery calcium (CAC) scoring to guide statin initiation reduces statin prescriptions without compromising major cardiovascular event prevention, while significantly improving medication adherence. Current guidelines from bodies like the ACC/AHA primarily utilize traditional risk assessment tools, such as the Pooled Cohort Equations, to identify individuals at intermediate to high risk for atherosclerotic cardiovascular disease (ASCVD) who would benefit from statin therapy.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Acute ischemic stroke causes substantial disability and risk of death. First-line therapy for patients with disabling acute stroke symptoms is intravenous thrombolysis (if no contraindications) within 4.5 hours of stroke onset and up to 24 hours in carefully selected patients not receiving mechanical thrombectomy; for large vessel occlusions, mechanical thrombectomy may be performed up to 24 hours after stroke onset in eligible patients.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
More patients achieved RALI than traditional remission with similar or lower rates of radiographic progression as well as low rates of high-risk characteristics and adverse long-term outcomes. These results support RALI as a point-of-care clinical target to inform management.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
Our results show that in this large household cohort, cavitary extent on chest radiograph and cough duration in people with TB were associated with increased TB transmission risk and showed dose-response relationships with TB infection. These simple, readily available indicators may help target preventive interventions in high-burden settings; however, associations with incident TB remain uncertain.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Per the results of this cohort study, NC FAI score provides prognostic performance comparable to CCTA FAI score and improves cardiovascular risk prediction and reclassification beyond CAC score. Elevated FAI score, derived from either CCTA or NCCT, should be interpreted as a risk-enhancing factor that may prompt intensification of established, evidence-based preventive measures and may serve as a potential future gatekeeper for the use of targeted anti-inflammatory treatments.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
15D and 15z cPS contain either WciZ-mediated or WcjE-mediated O-acetylation, respectively, while 15F contains both. Current typing schemes may not reliably resolve variants of vaccine serotypes, but we highlight how an anticipatory approach to capsule type discovery can address typing blind spots and refine vaccine surveillance efforts.
1/5 Early Lab
Evidence Meter · 1/5
Early Lab Signal
Discovered in human cells, organoids, or biochemical assays—promising biology, not yet tested in patients.
This first-in-kind translational study demonstrates that early prophylaxis with sacubitril/valsartan is a feasible and effective strategy to mitigate radiation-induced cardiotoxicity in children. These findings, underpinned by multi-modal validation from bench to bedside, challenge the reactive management paradigm in paediatric cardio-oncology and establish a foundational evidence base for a new standard of proactive heart care in childhood cancer survivors.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Sustained transthyretin suppression with eplontersen resulted in substantially lower myocardial ECV and favorable changes in cardiac structure, biventricular systolic function, and myocardial deformation compared with placebo (inactive comparison treatment) in a cohort of patients mostly not on background stabilizer at baseline. These findings provide randomized evidence that lowering circulating transthyretin modifies myocardial disease progression in ATTR-CM and support serial multiparametric CMR for characterizing myocardial treatment response.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Among patients with TTR amyloidosis with cardiomyopathy, eplontersen modestly attenuated deterioration in prognostically important measures of LV systolic, diastolic and right ventricular function, primarily among patients not receiving stabilizers at baseline. These findings complement the clinical findings of CARDIO-TTRansform and suggest that TTR silencing may attenuate progression of cardiac dysfunction in TTR amyloidosis with cardiomyopathy.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Improvements in LA reservoir strain and LV filling dynamics were associated with reductions in exercise PAWP (r=-0.46, P<0.001 and r=-0.65, P<0.0001, respectively). With respect to other prespecified CMR endpoints, semaglutide reduced LV mass, restored more physiologic LV geometry, and improved right ventricular function and biventricular myocardial mechanics.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
In AMI-CS, serial multimodality imaging characterized microvascular, tissue-level, and functional injury over 1 year. Cangrelor was associated with less acute MVO, lower remote native T1, and more complete recovery of LV function than crushed ticagrelor, without a difference in infarct size; these hypothesis-generating findings suggest differences in the microcirculation and non-infarcted myocardial injury but do not establish a treatment mechanism.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Undernutrition before and at treatment initiation is a potentially modifiable determinant of post-treatment lung impairment, with systemic inflammation mediating part of the effect. Nutritional assessment belongs in routine tuberculosis care, and nutritional support should be tested to prevent lung-function impairment in tuberculosis survivors.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
This work establishes SIR as a translationally relevant model of depression that predates conception and provides integrated MRI- and molecular-level biomarkers for dissecting mechanisms and informing early preventive strategies. Transcriptomic profiling of the thalamus revealed widespread, sex-dependent differences in gene expression, implicating pathways related to synaptic organization, protein synthesis, neuronal plasticity, and myelination.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
In this cohort study of infants born VPT, neonatal functional network organization was associated with cognitive performance at corrected age 2 and 3 years. The findings highlight the relevance of distributed connectivity involving the DMN and SMN to later cognitive outcomes and support further investigation of neonatal functional connectivity as an early marker of neurodevelopment.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
We review the evidence supporting these biomarkers for diagnosis, prognosis and regulatory use, and their role in clinical trials and in treatment decisions for approved MASH therapies. Composite scores, MAST, MEFIB, and MASH Resolution Index, combine imaging and blood tests for advanced fibrosis (tissue scarring) diagnosis and response assessment.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Elevated expression of several cytokines in the CSF of virologically suppressed PWH indicates persistent immune activity and supports the existence of a central nervous system (CNS) reservoir. Numerous cytokines showed favorable associations with NP data, including "proinflammatory" cytokines such as IL-6 and TNF-α and several chemotactic cytokines, whereas some "anti-inflammatory" cytokines such as IL-10 correlated positively with unfavorable neurodegenerative markers.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
This secondary analysis of the FLOWPROMOTE randomized clinical trial demonstrated that in statin-naive patients with CAD, more intensive lipid-lowering therapy was associated with significantly greater regression of total and noncalcified coronary plaque burden compared with intensive therapy. The extent of plaque regression was related to achieved LDL-C levels, supporting the potential for partial reversal of coronary atherosclerosis with intensive lipid reduction.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
These recommendations provide the first evidence-based guidance for the use of imaging in PMR, reinforcing clinical assessment as the cornerstone of diagnosis and positioning imaging as a context-driven adjunct. The study aims to develop international recommendations for the use of imaging in the diagnosis and assessment of polymyalgia rheumatica (PMR).
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Using ldCT as a reference standard, sCT demonstrated substantially higher sensitivity than T1wMRI and radiography. Intra- and inter-reader reliability and inter-modality agreement between ldCT and sCT were comparable, suggesting that discrepancies in lesion detection primarily reflect reader variability rather than inter-modality differences.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
In a large, multicenter cohort of HLHS patients, the MS/AA subtype with VCCs had the lowest TFS. Prenatal diagnosis of VCCs was associated with a lower TFS.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
This study found that PLAAT4 variants delineated SPDMLS, a clinically distinct leukodystrophy that should be considered in patients with unexplained spastic paraplegia and CNS WMH. Arachidonic acid-related lipids represent a candidate biomarker (measurable biological signal) for disease progression.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
In sum, ROR2 is a key driver of RVF pathogenesis through proteostatic disruption and thus provides a promising target to treat RVF. Published in Circulation, these peer-reviewed cardiology findings provide quantitative clinical evidence to inform risk stratification, therapeutic decision-making, and follow-up validation.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
This cross-sectional study demonstrates a shift in TIA care over time that suggests increased use of the ED to expedite evaluation for TIA that previously occurred during a brief hospitalization. This approach has consequences in terms of cost and ED throughput and may not be as feasible in rural hospitals as it is in urban hospitals.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
These findings support further evaluation of visugromab in MIBC. . There were no treatment-related discontinuations or treatment-related delays to surgery; grade 3-4 treatment-related side effects occurred in two (13%) and three (20%) patients treated with N + V or N + P, respectively.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
This randomized clinical trial found that treatment with RT-DXd demonstrated promising activity, with mostly low-grade toxic effects in immune-positive, ERBB2-negative EBC. Unlike immune-negative patients, many immune-positive patients who experienced pCR avoided standard chemotherapy, including anthracyclines, supporting further evaluation in biomarker (measurable biological signal)-selected populations.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Simedeutirom led to higher rates of MASH improvement without worsening of fibrosis (tissue scarring) than placebo (inactive comparison treatment) after 52 weeks, warranting further investigation in Phase 3 trials. Simedeutirom is a selective thyroid hormone receptor-β agonist that has previously been shown to reduce hepatic fat content in metabolic dysfunction-associated steatotic liver disease.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
1 min read·The Lancet Gastroenterology & Hepatology·
In this nonrandomized clinical trial, neoadjuvant SABR before nephrectomy and IVC thrombectomy appeared feasible with an acceptable safety profile. RFS met the prespecified Phase 2 screening criterion but remains exploratory and warrants further evaluation.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
In women with PCOS and MASLD, saroglitazar significantly improved hepatic steatosis, liver enzymes, lipid profile, and FibroScan AST score. These findings support further evaluation of saroglitazar in larger studies in women with PCOS.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
In immunocompetent patients with CM-PIIRS, adjunctive corticosteroid therapy was associated with sustained improvement in neurologic, visual, and radiologic outcomes with mixed improvement in hearing after a year of therapy, with mild residual deficits. Post-infectious inflammatory response syndrome (PIIRS) is an increasingly recognized complication of cryptococcal meningoencephalitis (CM) in non-HIV infected hosts with significant morbidity and risk of death.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
1 min read·The Journal of Infectious Diseases·
Patient & Student Companion
Everyday Lab & Drug Translator
Instant plain-English guides for common blood tests and prescriptions—what normal ranges mean, what high/low values signal, and what to ask your clinician.
Lab Marker3-Month Blood Sugar
HbA1c
Measures the percentage of red blood cell hemoglobin coated with glucose over roughly 90 days.
Normal: below 5.7% · Prediabetes: 5.7%–6.4%
6.5% or higher on two tests diagnoses diabetes; very low values can occur alongside hypoglycemia or hemolytic anemia.
Ask your doctor: “Does my HbA1c match my daily fasting/post-meal glucose trends?”
Estimated glomerular filtration rate—how many milliliters of blood your kidneys filter every minute.
Healthy adult filter rate: 90+ mL/min/1.73m²
Values persistently below 60 for 3+ months (or elevated urine albumin) mark chronic kidney disease; single dips can simply reflect dehydration or NSAID use.
Ask your doctor: “Should we pair eGFR with a urine albumin-to-creatinine test (uACR)?”